🇺🇸 FDA
Patent

US 11427820

Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA

granted A61KA61K31/56A61K31/57

Quick answer

US patent 11427820 (Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA) held by BIOMARIN TECHNOLOGIES B.V. expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN TECHNOLOGIES B.V.
Grant date
Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/56, A61K31/57, A61K31/573, A61K31/58